Research Paper Volume 16, Issue 5 pp 4396—4422

Figure 4. Drug treatment sensitivities of CWH22 and CLM22 organoids to traditional chemotherapies. (A) Dose-response curves of CWH22 and CLM22 organoids exposed to increasing concentrations of 5-fluorouracil, oxaliplatin, SN-38, regorafenib, VP-16, and sotorasib, and the half maximal inhibitory concentrations (IC₅₀) of each drug. (B) Representative images of CWH22 and CLM22 organoids exposed to three concentrations of 5-Fu and oxaliplatin (2 μM, 5 μM, and 10 μM; scale bars, 200 μm). (C) Quantitative analysis of CWH22, CLM22, and CRC16-Org cell viability following exposure to different concentrations of FO combined treatment (2 μM, 5 μM, and 10 μM; n = 3; data represented as the mean ± SD, ^**p < 0.01). (D) Preoperative and postoperative MRI coronal images of liver lesions during the first eight cycles treatment with mFOLFOX + bevacizumab strategies (scale bars, 5 cm).